Bill Cronin will lead CHOSA’s US business development and commercialization activities as the company advances the market introduction of Platin-DRP in the world’s largest oncology diagnostics market. Bill Cronin will be based in Kendall Square, Boston.

“The United States represents our most important commercial market, and Bill’s unique experience in building US operations for a Swedish oncology company aligns perfectly with CHOSA’s strategy. His commercial expertise and understanding of the US oncology ecosystem will significantly strengthen our ability to establish Platin-DRP in the market,” says Peter Buhl Jensen, CEO of CHOSA Oncology.

Bill Cronin

Bill Cronin brings more than two decades of executive leadership and commercial experience from the US life science, especially the oncology field and medical technology sectors. Most notably, he served as Chief Executive Officer of Dignitana AB from 2015 to 2022, where he led the commercialization of the Company’s FDA-cleared DigniCap Scalp Cooling System, used together with chemotherapy in breast cancer, in the United States. Under his leadership, Swedish Dignitana established its US commercial organization, expanded adoption at leading cancer centres, and transformed the United States into the Company’s primary commercial market. Dignitana was acquired by the British company Paxman Coolers – a process where Bill was deeply involved.

At CHOSA, Bill Cronin will focus on executing the company’s US commercialization strategy, including developing relationships with pharmaceutical companies, academic cancer centres, clinical laboratories, strategic partners, and key opinion leaders. He will also support the planned Research Use Only (RUO) launch of Platin-DRP and help position the company for future commercial expansion.

“Having helped bring a number of Scandinavian life science innovations to the US market, I find Platin-DRP one of the most exciting I’ve worked with yet. The CHOSA team has built something that can genuinely change how oncologists decide if platinum therapy is the right choice for their patients. I’m grateful for the chance to help lead that effort, and I’m looking forward to working alongside the really impressive team CHOSA has put together to get it there,” Bill Cronin comments.